NCT02316197View on ClinicalTrials.gov

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

June 29, 2017

Study Completion Date

June 29, 2017

Conditions
Advanced Solid TumorsChronic Lymphocytic Leukemia
Interventions
DRUG

MSC2490484A (M3814)

Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.

Trial Locations (7)

Unknown

Institut Jules Bordet, Brussels

UZ Leuven, Leuven

Rigshospitalet - Onkologisk KFE, Copenhagen

Herlev Hospital University of Copenhagen, Herlev

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

VU Medisch Centrum - Dept of Medical Oncology, Amsterdam

Erasmus Medisch Centrum - Parent, Rotterdam

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT02316197 - Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter